Nektar Therapeutics
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $307.7M | $165.4M | $230.8M | $200.7M | $148.9M | $81.2M | $71.5M | $159.0M |
| Cost of Revenue | $30.5M | $30.2M | $34.1M | $28.5M | $38.5M | $30.4M | $21.9M | $25.7M |
| Gross Profit | $277.2M | $135.2M | $196.7M | $172.2M | $110.4M | $50.8M | $49.6M | $133.4M |
| Gross Margin | 90.1% | 81.7% | 85.2% | 85.8% | 74.1% | 62.5% | 69.4% | 83.9% |
| Operating Expenses | ||||||||
| Research & Development | $268.5M | $203.8M | $182.8M | $147.7M | $190.0M | $148.7M | $126.8M | $108.1M |
| SG&A Expense | $52.4M | $44.3M | $43.3M | $40.9M | $40.5M | $41.6M | $46.8M | $41.0M |
| Operating Income | $-59.6M | $-112.9M | $-29.4M | $-16.5M | $-120.1M | $-141.2M | $-123.9M | $-28.3M |
| Operating Margin | -19.4% | -68.2% | -12.7% | -8.2% | -80.7% | -173.9% | -173.4% | -17.8% |
| Interest Expense | $22.1M | $22.5M | $18.3M | $17.9M | $18.5M | $15.5M | $10.2M | $11.2M |
| Pretax Income | $-96.1M | $-152.6M | $-80.7M | $-54.4M | $-159.8M | $-171.4M | $-133.0M | $-37.1M |
| Income Tax Expense | $616.0K | $876.0K | $506.0K | $-512.0K | $2.2M | $406.0K | $1.0M | $881.0K |
| Net Income | $-96.7M | $-153.5M | $-81.2M | $-53.9M | $-162.0M | $-171.9M | $-134.0M | $-37.9M |
| Net Margin | -31.4% | -92.8% | -35.2% | -26.9% | -108.8% | -211.7% | -187.4% | -23.9% |
| EPS (Basic) | $-0.62 | $-1.10 | $-0.61 | $-0.42 | $-1.40 | $-1.50 | $-1.19 | $-0.40 |
| EPS (Diluted) | $-0.62 | $-1.10 | $-0.61 | $-0.42 | $-1.40 | $-1.50 | $-1.19 | $-0.40 |
| Shares Outstanding (Basic) | 156.0M | 139.6M | 135.3M | 131.2M | 116.5M | 115.3M | 114.5M | 94.5M |
| Shares Outstanding (Diluted) | 156.0M | 139.6M | 135.3M | 131.2M | 116.5M | 115.3M | 114.5M | 94.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |